Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A.

Published byAlexis Bryant Modified over 9 years ago

Similar presentations

Presentation on theme: "Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A."— Presentation transcript:

1 Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A. Diamond, MD; Sanjay Kaul, MD Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California No conflicts to disclose

2 The N E W E N G L A N D J O U R N A L of M E D I C I N E ESTABLISHED IN 1812 JUNE 14, 2007 VOL. 356 NO. 24 Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Steven E. Nissen, M.D., and Kathy Wolski, M.P.H. Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death…that had borderline significance. CONCLUSIONS

3 Rosiglitazone Control No Event Rosiglitazone and Cardiovascular Events 27,833 Patients 158 Events 42 Trials 15,470 8672 12,205 MI Myocardial Infarction 0.59% 0.55% Event Rate

4 Rosiglitazone and Cardiovascular Events Myocardial Infarction 3000 2000 1000 0 Rosiglitazone Control MI No Event Patients Zero event trials 4 4 EXCLUDED N=38

5 Rosiglitazone and Cardiovascular Events Cardiovascular Death 3000 2000 1000 0 No Event Death Rosiglitazone Control Patients N=23 Zero event trials 19 19 EXCLUDED

6 Rosiglitazone and Cardiovascular Events Peto Meta-Analysis Odds Ratio 1 Myocardial Infarction Cardiovascular Death 1.43 (1.03-1.98) p=0.03 N=38 Odds Ratio 1.64 (0.98-2.14) p=0.06 N=23

7 Rosiglitazone and Cardiovascular Events Myocardial Infarction 3000 2000 1000 0 Rosiglitazone Control MI No Event Patients Zero event cells 6 20 INCLUDED

8 Rosiglitazone and Cardiovascular Events Cardiovascular Death 3000 2000 1000 0 No Event Death Rosiglitazone Control Patients Zero event cells 2 15 INCLUDED

9 Rosiglitazone and Cardiovascular Events Impact of Zero Events on Peto’s Odds Ratio ZeroO i -E i MIDeath Control  2015 Treatment  6 2

10 Rosiglitazone and Cardiovascular Events Cardiovascular Death 3000 2000 1000 0 No Event Death Rosiglitazone Control Patients

11 Rosiglitazone and Cardiovascular Events Continuity Correction 3000 2000 1000 0 Rosiglitazone Control k=1/2 k~1/N No Event Death Patients Sweeting et al, What to add to nothing? Stat Med 2006;23:1351-75.

12 Rosiglitazone and Cardiovascular Events Meta-Analytic Sensitivity Peto ( - ) Inverse variance 1/N ( - ) Inverse variance 1/2 ( - ) Mantel-Haenszel 1/N ( - ) Mantel-Haenszel 1/2 ( - ) Mantel-Haenszel 1/N (+) Mantel-Haenszel 1/2 (+) Uniform Bayes 1/N (+) Uniform Bayes 1/2 (+) Myocardial Infarction Cardiovascular Death Odds Ratio 0.5 1.0 1.5 2.0 2.5 3.0 *

13 Rosiglitazone and Cardiovascular Events Relative Risk Threshold Uncorrected Corrected Cardiovascular Death Magnitude of Harm Relative Risk Threshold Uncorrected Corrected Myocardial Infarction Probability of Harm

14 Rosiglitazone and Cardiovascular Events Limitations of the Published Meta-Analysis Not designed to assess outcomes No central adjudication of events No standardized definitions of events Limited sample size Short term duration No patient level data No sensitivity analysis No continuity correction

15 Rosiglitazone and Cardiovascular Events Key Questions Regarding the Published Meta-Analysis Rosiglitazone and Cardiovascular Events Key Questions Regarding the Published Meta-Analysis How robust is the meta-analysis? - Analytical methodology - Quality of the data What is the impact of heterogeneity on risk estimates? Are the risk estimates consistent with other studies?

16 Screened Phase 2, 3, 4 trials (N = 116) Rosiglitazone and Cardiovascular Events Flow Diagram of Inclusion/Exclusion Rosiglitazone and Cardiovascular Events Flow Diagram of Inclusion/Exclusion Retrieved for detailed evaluation (N = 48) Excluded on basis of: Lack of randomized comparator group <24 wks of drug exposure (N = 68) Included for meta-analysis (N = 42) Excluded on basis of: Lack of reported cardiovascular events (N = 6) Published literature Trial registries FDA summary report

17 Prespecified exclusion criteria Six trials omitted after taking a “peek” at outcomes (“no events”) Omission of these trials may potentially impact risk estimates Peer-reviewed data Included published (N=13) and unpublished (N=29) studies Uncertainty regarding quality due to lack of scientific peer review Patient-level data not available More robust time-to-event analysis not possible Endpoints None designed for CV endpoints; adjudication not standardized Potential for misclassification and ascertainment error Rosiglitazone and Cardiovascular Events Quality of Meta-Analysis Rosiglitazone and Cardiovascular Events Quality of Meta-Analysis

18 Pooling justified due to lack of statistical heterogeneity Cochran’s Q test of heterogeneity Limited ability to detect variability across studies with sparse data (low statistical power) Even if studies are statistically homogeneous there may be clinical heterogeneity in study design and population Rosiglitazone and Cardiovascular Events Is There Heterogeneity? Rosiglitazone and Cardiovascular Events Is There Heterogeneity?

19 Without diabetes ( N = 3) Alzheimer's (N = 1) Psoriasis (N = 2) Meta-analysis N = 42 With contraindication (CHF) N = 1 Without contraindication N = 38 With Diabetes N = 39 Rosiglitazone and Cardiovascular Events Clinical Heterogeneity in Patient Populations Rosiglitazone and Cardiovascular Events Clinical Heterogeneity in Patient Populations

20 Small trials (N=77-1549) Double-blind + open-label Follow-up (24-52 wks) N = 40 trials Meta-analysis N = 42 trials DREAM (N=5269) Impaired glucose tolerance ADOPT (N=4351) Newly diagnosed DM (<3 yrs) Large trials (N>4350) Double-blind Follow-up (3-5 yrs) N = 2 trials Rosiglitazone and Cardiovascular Events Clinical Heterogeneity in Trial Design Rosiglitazone and Cardiovascular Events Clinical Heterogeneity in Trial Design

21 RSG vs placebo N = 10 trials Meta-analysis N = 42 trials Head-to-head monotherapy (N = 4) RSG vs Sulfonylurea (N = 3) RSG vs Metformin/Sulfonylurea (N = 1) Add-on RSG vs placebo to Run-in Rx (N = 28) Metformin (N = 10) Sulfonylurea (N = 12) Insulin (N = 5) Usual care (N = 1) RSG vs standard Rx N = 32 trials Rosiglitazone and Cardiovascular Events Clinical Heterogeneity in Treatment Groups Rosiglitazone and Cardiovascular Events Clinical Heterogeneity in Treatment Groups

22 Absence of statistical heterogeneity does not imply absence of clinical heterogeneity Rosiglitazone and Cardiovascular Events Is There Heterogeneity? Rosiglitazone and Cardiovascular Events Is There Heterogeneity?

23 Myocardial Infarction Overall pooled data (N=26011) ADOPT (N=4351) DREAM (N=5269) Small trials combined (N=16391) 01234 Odds ratio Uncorrected (Peto) 1.45 (0.88-2.39) 1.43 (1.03-1.98) 01234 Odds ratio Corrected (MH/CC) 1.16 (0.76-1.78) 1.28 (0.95-1.72) Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups

24 Cardiovascular Death Overall pooled data (N=20445) ADOPT (N=4351) DREAM (N=5269) Small trials combined (N=10825) Odds ratio 012345 Uncorrected (Peto) 2.40 (1.17-4.91) 1.64 (0.98-2.74) Odds ratio 012345 Corrected (MH/CC) 1.51 (0.82-2.78) 1.33 (0.83-2.13) Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups

25 Myocardial Infarction Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups Uncorrected (Peto) Odds Ratio 0 1 2 3 4 5 1.37 1.52 1.40 Diabetes (-CHF) (N=38) RSG vs placebo (N=10) RSG vs antidiabetic Rx (N=32) RSG + SULF vs SULF (N=12) RSG + MET vs MET (N=10) 1.23 1.49 2.69 3.49 Other diseases (N=4) RSG + INS vs INS (N=5) Corrected (MH/CC) 0 1 2 3 4 5 Odds Ratio 1.25 1.31 1.27 1.11 1.05 1.90 2.77

26 Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups Rosiglitazone and Cardiovascular Events Meta-Analytic Subgroups Cardiovascular Death 0 2 4 6 8 10 Corrected (MH/CC) Odds Ratio 1.34 1.24 1.42 1.67 1.34 1.31 1.92 0 2 4 6 8 10 Uncorrected (Peto) Odds Ratio 1.58 1.50 1.79 2.43 1.75 2.10 5.37 Diabetes (-CHF) (N=38) RSG vs placebo (N=10) RSG vs antidiabetic Rx (N=32) RSG + SULF vs SULF (N=12) RSG + MET vs MET (N=10) Other diseases (N=4) RSG + INS vs INS (N=5)

27 Rosiglitazone and Cardiovascular Events Are the Risk Estimates Consistent? Rosiglitazone and Cardiovascular Events Are the Risk Estimates Consistent? 0123 FDA (N=42 trials) IHD Balanced Cohort Study (N=33363) GSK ICT analysis (N=42 trials) Cochrane Review (N=18 trials) RECORD (N=4407) CVD/MI/Stroke IHD CVD/MI/Stroke MI CV death MI Odds or hazard ratio

28 Sensitive to meta-analytic method Sensitive to continuity correction Sensitive to subgroup analysis If present, magnitude of harm is small We need more data! Rosiglitazone and Cardiovascular Events Conclusions Rosiglitazone and Cardiovascular Events Conclusions

Download ppt "Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A."

Similar presentations

Statistical Considerations for Implementing the FDA CV Guidance for T2DM Craig Wilson, PhD NIC-ASA Fall Meeting October 15, 2009.

Statistical Considerations for Implementing the FDA CV Guidance for T2DM Craig Wilson, PhD NIC-ASA Fall Meeting October 15, 2009.
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.

Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
ODAC May 3, 2004 1 Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.

ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.

By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.

Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Interpreting Adverse Signals in Diabetes Drug Development Programs Featured Article: Clifford J. Bailey, Ph.D. Diabetes Care Volume 36: 1-9 July, 2013.

Interpreting Adverse Signals in Diabetes Drug Development Programs Featured Article: Clifford J. Bailey, Ph.D. Diabetes Care Volume 36: 1-9 July, 2013.
Brar et al, JACC 2011 Impact of Platelet Reactivity When On-treatment With Clopidogrel on Mortality, MI or Stent Thrombosis After PCI Impact of Platelet.

Brar et al, JACC 2011 Impact of Platelet Reactivity When On-treatment With Clopidogrel on Mortality, MI or Stent Thrombosis After PCI Impact of Platelet.
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.
Lipid Modifying Therapies and Risk of Pancreatitis: A Meta-analysis Presented by: MaCie Rogers Pharm.d Candidate 2013.

Lipid Modifying Therapies and Risk of Pancreatitis: A Meta-analysis Presented by: MaCie Rogers Pharm.d Candidate 2013.
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.

ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Are the results valid? Was the validity of the included studies appraised?

Are the results valid? Was the validity of the included studies appraised?
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Slide Source: www.lipidsonline.org Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.

Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
CHP400: Community Health Program - lI Mohamed M. B. Alnoor Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past:

CHP400: Community Health Program - lI Mohamed M. B. Alnoor Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past:
Research Synthesis of Population-Based Prevalence Studies ORC Macro Benita J. O’Colmain, M.P.H. Wanda Parham, M.P.A. Arlen Rosenthal, M.A. Adrienne Y.

Research Synthesis of Population-Based Prevalence Studies ORC Macro Benita J. O’Colmain, M.P.H. Wanda Parham, M.P.A. Arlen Rosenthal, M.A. Adrienne Y.
CHP400: Community Health Program- lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Case Control Studies Present: Disease Past:

CHP400: Community Health Program- lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Case Control Studies Present: Disease Past:

Similar presentations

Ads by Google